JAK2 and Splenomegaly: However, after the discovery of dysregulation of the Janus kinase (JAK) pathway, most commonly JAK2 V617F mutation, in over half of MF patients,8, 9 targeted therapies with JAK inhibitors have demonstrated improvements in splenomegaly, burden of symptoms, and a potential gain in overall survival.10, 11